AVALO THERAPEUTICS, INC.
Last · —$11.84-0.17 (-1.42%)live · yahoo · 1h ago
Market cap$634.98M—
P/E · TTM—fwd — · eps —
Beta—vs S&P 500
Div yield—annual · TTM
52w range
——
Volume—session
| Revenue | $249,000 |
|---|---|
| Operating income | $-55.2M |
| Net income | $33,000 |
| Free cash flow | $-41.5M |
| Operating margin | -22169.1% |
| Net margin | 13.3% |
| Return on equity | 0.1% |
| Period | 2024 |
Loading chart…
OpenFilings analyst
Our analyst
From latest 10-K · 2026-03-23
- Sbc Revenue High
- Operating Cf Burn
- Net Margin Sharply Negative
- Cash Conversion Weak
- Cash Runway Low
- Accumulated Deficit High
- Rd Intensity High
Red flags
- Sbc Revenue High — SBC/Revenue 23086.4%
- Operating Cf Burn — Negative operating cash flow
- Net Margin Sharply Negative — Net margin -132642.4%
- Cash Conversion Weak — Cash conversion (CFO/Rev) -87216.9%
- Cash Runway Low — Cash runway ~0.3 years
- Accumulated Deficit High — Accumulated deficit / equity 540%
- Rd Intensity High — R&D/Revenue 84888.1%
Upcoming earnings
1:30 PM UTC+1
Period
Sep 2026
Est. EPS
−$0.56
Est. revenue
0
Earnings transcripts
- Issuer IR
Transcript Analyst Call 19 August 2026
AVANTIUM N.V.
- Issuer IR
Transcript Analyst Call 18 March 2026
AVANTIUM N.V.
- Issuer IR
Transcript Analyst Call 4 September 2025
AVANTIUM N.V.
- Issuer IR
Transcript Analyst Call 19 March 2025
AVANTIUM N.V.
- Issuer IR
Transcript Half Year 2024
AVANTIUM N.V.
- Issuer IR
Transcript Full Year 2023
AVANTIUM N.V.
Press & signals
- GlobeNewswire
Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
- GlobeNewswire
Avalo Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Updates